Cargando…
Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease
INTRODUCTION: Docosahexaenoic acid (DHA) and DHA-containing ethanolamine plasmalogens (PlsEtn) are decreased in the brain, liver and the circulation in Alzheimer's disease. Decreased supply of plasmalogen precursors to the brain by the liver, as a result of peroxisomal deficits is a process tha...
Autores principales: | Wood, Paul L, Smith, Tara, Lane, Nina, Khan, M Amin, Ehrmantraut, Greg, Goodenowe, Dayan B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260122/ https://www.ncbi.nlm.nih.gov/pubmed/22142382 http://dx.doi.org/10.1186/1476-511X-10-227 |
Ejemplares similares
-
In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursor
por: Wood, Paul L, et al.
Publicado: (2011) -
Pharmacokinetics, Mass Balance, Excretion, and Tissue Distribution of Plasmalogen Precursor PPI-1011
por: Smith, Tara, et al.
Publicado: (2022) -
Plasmalogen deficiency and neuropathology in Alzheimer's disease: Causation or coincidence?
por: Senanayake, Vijitha, et al.
Publicado: (2019) -
Cellular diamine levels in cancer chemoprevention: modulation by ibuprofen and membrane plasmalogens
por: Wood, Paul L, et al.
Publicado: (2011) -
Targeted metabolomic analyses of cellular models of pelizaeus-merzbacher disease reveal plasmalogen and myo-inositol solute carrier dysfunction
por: Wood, Paul L, et al.
Publicado: (2011)